LNC Therapeutics

Trending Articles

  1. Isospec launches analysis technology to identify unknown molecules The novel technology can facilitate the detection of trace amounts of unidentified molecules in nutraceutical formulations
  2. Kyowa Hakko’s IMMUSE powers Sensilab’s new IMMUNOFAR Biotic for enhanced immune support The incorporation of IMMUSE facilitates the strengthening of pDC functionality, promoting a healthy immune system
  3. Degradation of vitamins, probiotics and other active ingredients caused by exposure to heat, water and sunlight Vitamins and probiotics (and other active ingredients) can be substantially affected by exposure to heat, water and/or sunlight
  4. Glanbia acquires Flavor Producers for $300m The acquisition adds significantly to Glanbia's Better Nutrition platform, introducing novel flavour offerings
  5. The role of traceability in the nutraceutical supply chain The exponential growth of the nutraceutical sector, combined with the unprecedented growth in online marketplaces, makes nutraceuticals highly vulnerable to vast counterfeiting...

Upcoming event

Vitafoods Europe

14–16 May 2024 | Exhibition | Palexpo, Geneva See all

Related Content

Ingredients

LNC acquires exclusive worldwide licence for Christensenella-based mood disorder therapeutic

Deal strengthens LNC's portfolio of intellectual property and live biotherapeutic products for new applications in areas of high unmet medical need
Research & Development

LNC Therapeutics forms advisory board for Christensenella research

The gut microbiome-based drug research and discovery specialist has chosen experts to advise the future of its Christensella R&D programme
Ingredients

LNC Therapeutics dedicates research platform to Christensenella genus

With substantial scientific assistance, the new unit aims to enhance and capitalise on biotechnology- and health-related research
Ingredients

Christensenella: The cornerstone of the gut microbiota?

LNC Therapeutics, a French biotechnology company specialising in gut microbiome-based drugs, is taking a closer look at a new cluster of bacteria, <i>Christensenella</i>, and its role in regulating the intestinal microbiome in various chronic metabolic diseases
Subscribe now